<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-58" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pitavastatin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhatti</surname>
            <given-names>Harneet</given-names>
          </name>
          <aff>SUNY Upstate Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tadi</surname>
            <given-names>Prasanna</given-names>
          </name>
          <aff>Asram Medical College, Eluru, India</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Harneet Bhatti declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Prasanna Tadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>4</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-58.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Pitavastatin is a medication used in the management and treatment of hypercholesterolemia and dyslipidemia. It is in the statin class of drugs. This activity reviews the indications, action, and contraindications for pitavastatin as a valuable agent in managing dyslipidemia. This activity will highlight the mechanism of action, adverse event profile, and other key factors, including dosing, pharmacokinetics, monitoring, and relevant interactions pertinent for interprofessional team members in the management of patients with dyslipidemia and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the mechanism of action of pitavastatin.</p></list-item><list-item><p>Identify the possible adverse effects of pitavastatin.</p></list-item><list-item><p>Review the appropriate monitoring when using pitavastatin as hyperlipidemia therapy.</p></list-item><list-item><p>Outline the importance of improving care coordination amongst the interprofessional team to facilitate the delivery of care when initiating patients on statin therapy in order to improve outcomes for patients receiving statins.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=58&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=58">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-58.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Pitavastatin is currently FDA approved for the management of primary dyslipidemia and mixed dyslipidemia as adjunctive therapy to dietary changes to help lower total cholesterol, low-density lipoprotein cholesterol (LDL), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL).<xref ref-type="bibr" rid="article-58.r1">[1]</xref><xref ref-type="bibr" rid="article-58.r2">[2]</xref><xref ref-type="bibr" rid="article-58.r3">[3]</xref>&#x000a0;It is also FDA approved to treat heterozygous familial hypercholesterolemia (HeFH) in pediatric patients over 8 years of age.<xref ref-type="bibr" rid="article-58.r4">[4]</xref><xref ref-type="bibr" rid="article-58.r5">[5]</xref>&#x000a0;Unlike other statins, pitavastatin has not been studied in any large randomized controlled study to determine whether its use is associated with decreased cardiovascular events.</p>
      </sec>
      <sec id="article-58.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Pitavastatin competitively inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in the cholesterol biosynthesis pathway. Inhibiting this enzyme decreases the production of mevalonic acid from HMG-CoA. This enzymatic inhibition, in turn, increases the number of LDL receptors expressed on hepatocytes to compensate for the loss of mevalonic acid and results in greater LDL catabolism.<xref ref-type="bibr" rid="article-58.r6">[6]</xref><xref ref-type="bibr" rid="article-58.r7">[7]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>
<bold>Absorption</bold>
</p>
        <p>Peak plasma concentrations of pitavastatin are reached within approximately 1 hour after oral administration. It has a bioavailability greater than 60%. It has some absorption in the colon; however, its absorption mainly occurs in the small intestine. In comparison to all other statins, pitavastatin reaches peak plasma concentrations the fastest and has the highest bioavailability.</p>
        <p>
<bold>Distribution&#x000a0;</bold>
</p>
        <p>Pitavastatin is largely bound to protein (&#x0003e;99%), primarily to albumin and alpha-1 acid glycoprotein, with a mean volume of distribution of 148L.&#x000a0;</p>
        <p><bold>Metabolism</bold>&#x000a0;</p>
        <p>Pitavastatin is mainly metabolized in the liver by UGT1A3 and UGT2B7 and minimally by CYP2C9 and CYP2C8.</p>
        <p>
<bold>Excretion</bold>
</p>
        <p>The half-life of pitavastatin is approximately 12 hours. The majority of pitavastatin (79%) is excreted in the feces, whereas approximately 15% is excreted in the urine.<xref ref-type="bibr" rid="article-58.r6">[6]</xref></p>
      </sec>
      <sec id="article-58.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Pitavastatin is available as 1 mg, 2 mg, and 4 mg tablets for oral administration. Patients may take the drug at any time of the day; however, the time of day should remain consistent. Patients can take it with or without food.&#x000a0;</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>Pitavastatin is a moderate-intensity statin. The dose range for pitavastatin is between 1 mg to 4 mg once daily; 2 mg once daily is the recommended starting dosage, and the maximum dose is 4 mg once daily. The actual starting dosage and maintenance dosage should be individualized to the patient's characteristics and goals of therapy as per the American College of Cardiology/American Heart Association Guidelines.<xref ref-type="bibr" rid="article-58.r1">[1]</xref><xref ref-type="bibr" rid="article-58.r8">[8]</xref>&#x000a0;Lipid levels should be assessed four weeks after starting therapy to determine whether the response is appropriate and whether the dosage is appropriate. &#x000a0;</p>
        <p><bold>Pediatric Dosing</bold>&#x000a0;</p>
        <p>For children aged eight years and older, for management of HeFH, 2 mg once daily is the recommended starting dosage. Lipid levels should be re-assessed four weeks after initiating therapy and adjusted accordingly. The maximum recommended dosage is 4 mg once daily.<xref ref-type="bibr" rid="article-58.r4">[4]</xref><xref ref-type="bibr" rid="article-58.r5">[5]</xref></p>
        <p>
<bold>Geriatric Dosing&#x000a0;</bold>
</p>
        <p>Research has determined no significant difference in terms of safety and efficacy was determined between geriatric patients (age greater than 65) and younger patients.<xref ref-type="bibr" rid="article-58.r7">[7]</xref><xref ref-type="bibr" rid="article-58.r9">[9]</xref></p>
        <p>
<bold>Renal Impairment</bold>
</p>
        <p>Patients with a glomerular filtration rate between 15&#x000a0;to 59 mL/min/1.73 m not requiring hemodialysis, and patients with end-stage renal disease requiring hemodialysis should initiate pitavastatin at 1 mg once daily to a maximum dose of 2 mg once daily.&#x000a0;</p>
        <p>
<bold>Hepatic Impairment</bold>
</p>
        <p>Pitavastatin is contraindicated in the presence of active liver disease and patients with unexplained elevated liver enzymes.<xref ref-type="bibr" rid="article-58.r9">[9]</xref><xref ref-type="bibr" rid="article-58.r10">[10]</xref></p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Pitavastatin is mainly metabolized by glucuronidation via liver UGTs, and there is comparably only minimal metabolism by cytochrome P450 enzymes.<xref ref-type="bibr" rid="article-58.r6">[6]</xref>
<list list-type="bullet"><list-item><p>The following drugs may decrease the serum concentration of pitavastatin: darunavir/ritonavir, lopinavir/ritonavir, ezetimibe, digoxin, and itraconazole.</p></list-item><list-item><p>The following drugs may increase the serum concentration of pitavastatin: cyclosporine, erythromycin, rifampin, atazanavir, gemfibrozil, fenofibrate, enalapril, and diltiazem.<xref ref-type="bibr" rid="article-58.r7">[7]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-58.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most commonly reported adverse effects related to pitavastatin use include back pain, constipation, diarrhea, myalgia, and pain in the extremities. Reports exist of rash, pruritus, and urticaria. There are also reports of myopathy and rhabdomyolysis, leading to acute renal failure. Pitavastatin use can also cause lab abnormalities, including elevated creatine phosphokinase, transaminases (aspartate aminotransferase [AST]/serum glutamic-oxaloacetic transaminase, or alanine aminotransferase [ALT]/serum glutamic-pyruvic transaminase), alkaline phosphatase, bilirubin, and glucose. High fasting serum glucose levels and high HgA1c levels have also occurred with pitavastatin use.<xref ref-type="bibr" rid="article-58.r10">[10]</xref><xref ref-type="bibr" rid="article-58.r11">[11]</xref><xref ref-type="bibr" rid="article-58.r12">[12]</xref></p>
      </sec>
      <sec id="article-58.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Pitavastatin use is contraindicated in patients with known hypersensitivity, including rash, pruritus, urticaria, to any component of this drug. Its use is also contraindicated in patients with active liver disease or unexplained elevated levels of hepatic transaminases. Pregnant women or ones who may become pregnant should also avoid pitavastatin use. As pitavastatin is known to pass into breast milk, the recommendation is that nursing mothers also avoid pitavastatin use.<xref ref-type="bibr" rid="article-58.r10">[10]</xref><xref ref-type="bibr" rid="article-58.r13">[13]</xref></p>
      </sec>
      <sec id="article-58.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Liver function tests and a lipid panel should be performed before starting pitavastatin to establish baseline levels. A repeat lipid panel should be obtained six weeks after initiation. Once stable, the monitoring of lipids can be yearly. Liver function tests are repeatable as clinically necessary.</p>
      </sec>
      <sec id="article-58.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>A common side effect of pitavastatin toxicity is myalgia. In the setting of overdose, there is no known treatment. Patients should be provided with supportive measures and should receive treatment for any symptoms. Given the high protein binding ratio of pitavastatin, hemodialysis would not be beneficial.</p>
      </sec>
      <sec id="article-58.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The management of hyperlipidemia is an essential aspect of healthcare, given the risk of cardiovascular disease associated with it. Interprofessional communication and communication with the patient from all members of the patient&#x02019;s health care team is vital to help decrease the risk of&#x000a0;cardiovascular events.&#x000a0;Physicians and pharmacists can work together to determine which medications will best help a patient in the setting of their known comorbidities. As a group, clinicians (including NPs and PAs), pharmacists, and nursing staff can relay information regarding the risks associated with hyperlipidemia and the importance of medication compliance. Medication compliance may improve if patients are aware of the long-term benefits of statin use. Pharmacists can also further provide information regarding side effects. Such information from a reliable source may help reduce the fear associated with statin use and improve medication compliance.</p>
        <p>Follow-up visits with a physician may increase medication compliance as well, given that it provides an opportunity for patients to learn more about hyperlipidemia and its management.<xref ref-type="bibr" rid="article-58.r14">[14]</xref>&#x000a0;[Level 3] One study determined that telephone calls to patients every six months may also help improve adherence to medications.<xref ref-type="bibr" rid="article-58.r15">[15]</xref>&#x000a0;Also, nutritionists and dieticians can play an essential role in managing hyperlipidemia as they help guide patients towards individualized lifestyle modifications. As with any medication regimen, interprofessional collaboration and communication when using pitavastatin to treat hypercholesterolemia will improve therapeutic outcomes and reduce unwanted side effects and interactions. [Level 5]</p>
      </sec>
      <sec id="article-58.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=58&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=58">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/58/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=58">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-58.s11">
        <title>References</title>
        <ref id="article-58.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoy</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Pitavastatin: A Review in Hypercholesterolemia.</article-title>
            <source>Am J Cardiovasc Drugs</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>2</issue>
            <fpage>157</fpage>
            <page-range>157-168</page-range>
            <pub-id pub-id-type="pmid">28130659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tomlinson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>ZM</given-names>
              </name>
            </person-group>
            <article-title>An evaluation of pitavastatin for the treatment of hypercholesterolemia.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>103</fpage>
            <page-range>103-113</page-range>
            <pub-id pub-id-type="pmid">30482061</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pirillo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Catapano</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Pitavastatin and HDL: Effects on plasma levels and function(s).</article-title>
            <source>Atheroscler Suppl</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>27</volume>
            <fpage>e1</fpage>
            <page-range>e1-e9</page-range>
            <pub-id pub-id-type="pmid">28716185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Benekos</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kosmeri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vlahos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Milionis</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Nine-year overview of dyslipidemia management in children with heterozygous familial hypercholesterolemia: a university hospital outpatient lipid clinic project in Northwestern Greece.</article-title>
            <source>J Pediatr Endocrinol Metab</source>
            <year>2020</year>
            <month>Apr</month>
            <day>28</day>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>533</fpage>
            <page-range>533-538</page-range>
            <pub-id pub-id-type="pmid">32084003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Braamskamp</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Stefanutti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Langslet</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Drogari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wiegman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hounslow</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJ</given-names>
              </name>
              <collab>PASCAL Study Group</collab>
            </person-group>
            <article-title>Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk.</article-title>
            <source>J Pediatr</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>167</volume>
            <issue>2</issue>
            <fpage>338</fpage>
            <page-range>338-43.e5</page-range>
            <pub-id pub-id-type="pmid">26059337</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mukhtar</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reckless</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Pitavastatin.</article-title>
            <source>Int J Clin Pract</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>239</fpage>
            <page-range>239-52</page-range>
            <pub-id pub-id-type="pmid">15854203</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kajinami</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Takekoshi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor.</article-title>
            <source>Cardiovasc Drug Rev</source>
            <year>2003</year>
            <season>Fall</season>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>199</fpage>
            <page-range>199-215</page-range>
            <pub-id pub-id-type="pmid">12931254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Betteridge</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pitavastatin - results from phase III &#x00026; IV.</article-title>
            <source>Atheroscler Suppl</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>8</fpage>
            <page-range>8-14</page-range>
            <pub-id pub-id-type="pmid">21193153</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chamberlin</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Benefit-risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients.</article-title>
            <source>Clin Interv Aging</source>
            <year>2015</year>
            <volume>10</volume>
            <fpage>733</fpage>
            <page-range>733-40</page-range>
            <pub-id pub-id-type="pmid">25931816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <chapter-title>Pitavastatin</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>12</month>
            <day>1</day>
            <pub-id pub-id-type="pmid">31643396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flores</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Pitavastatin Nissan/Kowa Yakuhin/Novartis/Sankyo.</article-title>
            <source>Curr Opin Investig Drugs</source>
            <year>2002</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>9</issue>
            <fpage>1334</fpage>
            <page-range>1334-41</page-range>
            <pub-id pub-id-type="pmid">12498010</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teramoto</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Pitavastatin: clinical effects from the LIVES Study.</article-title>
            <source>Atheroscler Suppl</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>285</fpage>
            <page-range>285-8</page-range>
            <pub-id pub-id-type="pmid">22152283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eiland</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Luttrell</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Use of statins for dyslipidemia in the pediatric population.</article-title>
            <source>J Pediatr Pharmacol Ther</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>160</fpage>
            <page-range>160-72</page-range>
            <pub-id pub-id-type="pmid">22477808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brookhart</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Patrick</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Schneeweiss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Avorn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dormuth</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shrank</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>van Wijk</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Cadarette</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Canning</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>DH</given-names>
              </name>
            </person-group>
            <article-title>Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use.</article-title>
            <source>Arch Intern Med</source>
            <year>2007</year>
            <month>Apr</month>
            <day>23</day>
            <volume>167</volume>
            <issue>8</issue>
            <fpage>847</fpage>
            <page-range>847-52</page-range>
            <pub-id pub-id-type="pmid">17452550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-58.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jelinek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vale</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Liew</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Grigg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hare</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Best</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>The COACH program produces sustained improvements in cardiovascular risk factors and adherence to recommended medications-two years follow-up.</article-title>
            <source>Heart Lung Circ</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>388</fpage>
            <page-range>388-92</page-range>
            <pub-id pub-id-type="pmid">19648058</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
